Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo.
Falcinelli SD, Peterson JJ, Turner AW, Irlbeck D, Read J, Raines SL, James KS, Sutton C, Sanchez A, Emery A, Sampey G, Ferris R, Allard B, Ghofrani S, Kirchherr JL, Baker C, Kuruc JD, Gay CL, James LI, Wu G, Zuck P, Rioja I, Furze RC, Prinjha RK, Howell BJ, Swanstrom R, Browne EP, Strahl BD, Dunham RM, Archin NM, Margolis DM.
Falcinelli SD, et al. Among authors: ghofrani s.
J Clin Invest. 2022 Apr 15;132(8):e157281. doi: 10.1172/JCI157281.
J Clin Invest. 2022.
PMID: 35426377
Free PMC article.